4-chlorokynurenine

4-Chlorokynurenine (also known as AV-101 or L-4-chlorokynurenine) is a prodrug that is converted into 7-chlorokynurenic acid (7-Cl-KYNA), an antagonist of the N-methyl-D-aspartate receptor (NMDAR), in the brain. It is being developed as a potential treatment for various neurological and psychiatric disorders.

Chemistry

4-Chlorokynurenine is a chlorinated derivative of kynurenine, an intermediate in the kynurenine pathway of tryptophan metabolism. It is a prodrug for 7-chlorokynurenic acid, a potent and selective antagonist of the glycine site of the NMDAR.

Pharmacology

After oral administration, 4-chlorokynurenine crosses the blood-brain barrier and is converted into 7-Cl-KYNA by astrocytes. 7-Cl-KYNA is a potent and selective antagonist of the glycine site of the NMDAR, which is implicated in the pathophysiology of several neurological and psychiatric disorders.

Clinical development

4-Chlorokynurenine is being developed as a potential treatment for several conditions, including major depressive disorder, neuropathic pain, epilepsy, schizophrenia, and Parkinson's disease. It is currently in clinical trials.

See also

• Kynurenine pathway
• NMDA receptor antagonist
• Prodrug

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian